ArticlePsychopharmacology2026
A repeated low-dose regimen of MDMA has transient next-day effects on locomotor activity, anxiety-like behavior, and brain serotonin levels, with no effect on anhedonia-like behavior, in both female and male rats.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
rationaleMDMA (3–4 methylenedioxymethamphetamine) assisted psychotherapy has gained considerable attention as a potential adjuvant therapy for post-traumatic stress disorder (PTSD). Reports of the nonmedical use of MDMA suggest its adverse effects may include anxiety and anhedonia. However, the time course of these signs and symptoms and the potential alterations in neurotransmitter levels that may underlie these conditions are not well understood.
methodsWe subjected cohorts of male and female Sprague Dawley rats to MDMA (2.5 or 5 mg/kg) or saline (1 ml/kg), with each dose given three times at two-hour intervals. Anxiety-like behavior (open field test [OFT]/elevated plus maze [EPM]/light dark box [LDB] assays) was measured 1 and 15 days after MDMA. Anhedonia-related behavior (sucrose preference test [SPT]) was also measured for five successive days and at 15 days after MDMA. Finally, brains were isolated following behavioral testing and analyzed for monoamine levels in regions of interest.
resultsOne day after exposure, the rats treated with repeated 2.5 mg/kg (but not 5 mg/kg) MDMA showed mild anxiety-like behavior in the OFT but this was confounded by reduced locomotion. Anxiety-like behavior was not affected 15 days after MDMA administration. Sucrose preference increased over time but was not impacted by treatment or sex. High-pressure liquid chromatography (HPLC) analysis revealed a significant reduction in serotonin levels in the nucleus accumbens, but not prefrontal cortex or dorsal hippocampus, of rats treated with 2.5 and 5 mg/kg MDMA one day after exposure.
conclusionThese findings indicate that mild effects following a one-day MDMA administration at the current doses (2.5 and 5 mg/kg) may occur in both sexes, but these effects are transient. These data suggest that clinical use of MDMA at low doses may be tolerated and should not limit therapeutic usefulness.
Indexed as
Identifiers
41775927What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.